Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 20/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20670663 | 0.90 | OPRK1 (0.67) | OPRK1OPRM1 | |
| SCHEMBL29664164 | 0.90 | OPRK1 (0.67) | OPRK1OPRM1 | |
| SCHEMBL20670628 | 0.88 | OPRK1 (0.64) | OPRK1OPRM1 | |
| SCHEMBL20670932 | 0.86 | OPRK1 (0.64) | OPRK1OPRM1OPRD1KCNH2 | |
| SCHEMBL20499958 | 0.86 | OPRK1 (0.65) | OPRK1OPRM1OPRD1KCNH2 | |
| SCHEMBL20670528 | 0.85 | OPRK1 (0.67) | OPRK1OPRM1OPRD1KCNH2 | |
| SCHEMBL20670800 | 0.85 | OPRK1 (0.65) | OPRK1OPRM1OPRD1KCNH2 | |
| SCHEMBL20670513 | 0.84 | OPRK1 (0.67) | OPRK1OPRM1OPRD1KCNH2 | |
| SCHEMBL20670898 | 0.84 | OPRK1 (0.69) | OPRK1OPRM1OPRD1KCNH2 | |
| SCHEMBL20670939 | 0.84 | OPRK1 (0.53) | OPRK1OPRM1OPRD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11124504-B2 | Kappa opioid receptor antagonists and products and methods related thereto | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210047310-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2021-02-18 | — | — | US | disclosed |
| US-10676469-B2 | Kappa opioid receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190023700-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 2/4885 |
| US-11124504-B2 | Kappa opioid receptor antagonists and products and methods related thereto | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 2/4885 |
| US-20190023700-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 2/4885 |
| US-10676469-B2 | Kappa opioid receptor antagonists and products and methods related thereto | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 2/4885 |
| US-20210047310-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.